6
|
Pimm J, McQuillin A, Thirumalai S, Lawrence J, Quested D, Bass N, Lamb G, Moorey H, Datta SR, Kalsi G, Badacsonyi A, Kelly K, Morgan J, Punukollu B, Curtis D, Gurling H. The Epsin 4 gene on chromosome 5q, which encodes the clathrin-associated protein enthoprotin, is involved in the genetic susceptibility to schizophrenia. Am J Hum Genet 2005; 76:902-7. [PMID: 15793701 PMCID: PMC1199380 DOI: 10.1086/430095] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2004] [Accepted: 03/04/2005] [Indexed: 11/03/2022] Open
Abstract
Chromosome 5q33 is a region that has previously shown good evidence of linkage to schizophrenia, with four LOD scores >3.00 in independent linkage studies. We studied 450 unrelated white English, Irish, Welsh, and Scottish research subjects with schizophrenia and 450 ancestrally matched supernormal controls. Four adjacent markers at the 5' end of the Epsin 4 gene showed significant evidence of linkage disequilibrium with schizophrenia. These included two microsatellite markers, D5S1403 (P=.01) and AAAT11 (P=.009), and two single-nucleotide-polymorphism markers within the Epsin 4 gene, rs10046055 (P=.007) and rs254664 (P=.01). A series of different two- and three-marker haplotypes were also significantly associated with schizophrenia, as confirmed with a permutation test (HapA, P=.004; HapB, P=.0005; HapC, P=.007; and HapD, P=.01). The Epsin 4 gene encodes the clathrin-associated protein enthoprotin, which has a role in transport and stability of neurotransmitter vesicles at the synapses and within neurons. A genetically determined abnormality in the structure, function, or expression of enthoprotin is likely to be responsible for genetic susceptibility to a subtype of schizophrenia on chromosome 5q33.3.
Collapse
Affiliation(s)
- Jonathan Pimm
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Andrew McQuillin
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Srinivasa Thirumalai
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Jacob Lawrence
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Digby Quested
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Nicholas Bass
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Graham Lamb
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Helen Moorey
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Susmita R. Datta
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Gursharan Kalsi
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Allison Badacsonyi
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Katie Kelly
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Jenny Morgan
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Bhaskar Punukollu
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - David Curtis
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| | - Hugh Gurling
- Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, Camden and Islington Mental Health and Social Care Trust, St. Pancras Hospital, West London Mental Health Trust, Hammersmith and Fulham Mental Health Unit and St. Bernard’s Hospital, and Queen Mary College, University of London and East London and City Mental Health Trust, Royal London Hospital, London; West Berkshire National Health Service (NHS) Trust, Reading, United Kingdom; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; and Gloucestershire Partnership NHS Trust, Gloucester, United Kingdom
| |
Collapse
|